Both routes, priced on one page
Nineteen of the sixty-five sellers here price a compounded route and a brand-name route, and far fewer put every figure on the same page at the same time. Pallas does. Two compounded preparations and four branded products, each with a number beside it, before any intake.
That is worth more than it sounds. The gap between a compounded preparation and an FDA-approved finished drug is the single largest decision in this category, and most readers have to visit two sites and start two intakes to see both sides of it. Here it is one scroll.
The branded figures are cash-pay rates, and Pallas says on the same page that brand-name medications are billed at pharmacy cash-pay rates which can vary by product and dose. They are not an estimate of what a plan would charge, and they are not fixed.
The averaging, and why the qualifier matters here
Pallas does not bill the ongoing compounded figure every month. It bills a single larger amount every twelve weeks and divides that by three itself, printing the result as an average. The word average is Pallas's own, and it is doing real work.
This roster records the averaged figure because the seller states it in those words, and puts the amount actually charged and its term into the qualifier where they cannot be separated from the number. Read that qualifier. On this provider it is the difference between a monthly bill and a quarterly one.
That structure is not a trick. A prepaid term gives a seller committed revenue and the discount is what pays for it. It becomes a problem only when a reader compares the divided figure against another company's genuine month-to-month rate, which is exactly what a comparison table invites.
No membership, and two charges that are not the medication
Pallas states three times on its priced page that there is no separate membership fee and no per-visit charge. Twenty-six of the sixty-five sellers here say something equivalent, and a stated absence is worth more than silence: this roster records a membership as absent only when a seller says so.
Two other charges do exist, and they are in the terms rather than on the priced page. A deposit is taken at checkout, which a promotional discount can reduce, and a processing fee is retained on each refunded payment. Pallas says the refund fee never applies to an order a clinician declines or does not fulfil.
Neither is a membership and neither is hidden, but neither is on the page a shopper reads either. If you expect to cancel, the refund terms are the paragraph to read before the price is.
The clinician disclosure is the strongest sentence on this row
Pallas names its advising physician with credentials and a federal provider number, and tells the reader to verify that number in the national registry. Five sellers on this roster publish a prescriber's number that way.
It goes further than that. The site states that a patient is given the name and licence information of their specific treating clinician before any prescription is issued. That is a stronger commitment than naming a medical director, because it is about the person who will actually make a decision about you.
One qualification travels with it. The clinical care is delivered by an outside medical group, and that same group delivers care for another seller in this comparison. Two companies, two prices, one clinical operation behind them. Nothing about that is improper, and it does mean shortlisting both is not the second opinion it looks like.
The state footprint, and a widely repeated number that is about something else
Pallas publishes its footprint in its FAQ: all fifty states plus the District of Columbia, with seven named states and the District requiring one short video visit rather than a fully asynchronous intake. Thirty-two of the sixty-five sellers here publish any state list at all.
A comparison site elsewhere reports Pallas as operating in forty-three states. That number is real and it is about something else entirely: it is the count of states where the visit is fully asynchronous. Subtracting it from fifty produces a coverage claim nobody made.
The practical version is short. Pallas will serve you wherever you live in the United States, and in eight places you will be on a short video call to get there.
Pallas Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $199/moThe seller's own average of a twelve-week prepayment, in its own words: "Compounded semaglutide is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime." The amount billed is $597 every twelve weeks, not this figure every month. | September 2026source |
| Tirzepatide (compounded) | $299/moThe seller's own average of a twelve-week prepayment: "Compounded tirzepatide is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime." The amount billed is $897 every twelve weeks. | September 2026source |
| Semaglutide (brand) | $1349/moCash-pay, billed monthly, as Pallas publishes it: "Brand-name prices are cash-pay, billed monthly" and "Brand-name medications are billed at pharmacy cash-pay rates, which can vary by product and dose." | September 2026source |
| Semaglutide (brand) | $1299/moCash-pay, billed monthly, under the same page note that brand-name rates "can vary by product and dose". | September 2026source |
| Tirzepatide (brand) | $1069/moCash-pay, billed monthly, under the same page note that brand-name rates "can vary by product and dose". | September 2026source |
| Tirzepatide (brand) | $1349/moCash-pay, billed monthly, under the same page note that brand-name rates "can vary by product and dose". | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 65 providers reviewed here are paid partners today; the other 61 are not. See how this works.
See Pallas Health's current price →Good fit if
- Readers deciding between a compounded preparation and an FDA-approved product who want both cash figures from one seller on one page.
- Buyers who want the clinician who will write their prescription named, with a licence number, before the prescription exists.
- People who want a seller to state in writing that no membership and no per-visit fee apply.
- Readers who want the state footprint published, including which states need a live video visit rather than a form.
Look elsewhere if
- Anyone who wants a genuine month-to-month compounded rate. After the first month Pallas bills every twelve weeks, and the monthly figure is its own division of that.
- Readers who need the compounding pharmacy named. Pallas names a medical group and not a pharmacy.
- Buyers comparing on advertised entry figures, since both compounded drugs open lower than they continue.
- People shortlisting several sellers as independent clinical opinions. Pallas's care is delivered by a group that also serves another company in this comparison.
How this review was verified
- Read the GLP-1 treatments page in a browser and audited every dollar element for computed opacity, visibility, inherited hidden state and a real laid-out rectangle before recording a figure.
- Recorded the seller's own averaged ongoing figure and put the amount actually billed and its twelve-week term in the qualifier, so the two cannot be read apart.
- Recorded both first-month rates as introductory offers rather than as prices, because they describe one month rather than a year.
- Confirmed the operating company and the governing-law clause on the terms page, and logged the checkout deposit and refund processing fee from that same document rather than from the priced page.
- Read the state-footprint answer in the seller's own FAQ and compared it against a third-party figure that turned out to describe asynchronous visits rather than coverage. The seller's own sentence was used.
- Searched the agency's published warning-letter record for both the trading name and the operating company, 2017 to 2026, and found nothing. That search covers warning letters only; untitled letters are published separately and were not searched.